NLS Pharmaceutics Invites Patients, Caregivers And Other Interested Parties To Attend International Narcolepsy Webinar

News and research before you hear about it on CNBC et al. Claim your 1-week free trial for Street Insider Premium here.

ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2022 / NLS Pharmaceutics Ltd. (NASDAQ: NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Wake Up Narcolepsy, a leading patient advocacy organization dedicated to serving the narcolepsy community, will host an international online narcolepsy webinar that will take place on January 20-21, 2022. NLS Pharmaceutics et d ‘ Other leading pharmaceutical companies focused on the treatment of narcolepsy are the event sponsors, and the Company invites patients, caregivers and other interested parties to attend the webinar.

Webinar Details:

Day 1: January 20, 2022 10:45 a.m. to 3:00 p.m. Eastern Time (4:45 p.m. to 9:00 p.m. CET)

Day 2: January 21, 2022 10:45 a.m. to 2:45 p.m. Eastern Time (4:45 p.m. to 8:45 p.m. CET)

A presentation on narcolepsy in general, including a discussion of mazindol as a potential treatment for narcolepsy and the ongoing Phase 2 clinical trial of NLS Pharmaceutics for Quilience® (mazindol ER) will take place on January 20, 2022 at 12:45 p.m. ET (6:45 p.m.). HEC). To join the webinar, please visit:

About narcolepsy upon waking up

Wake Up Narcolepsy is a 501 (c) (3) nonprofit organization dedicated to narcolepsy awareness, education and research for improved treatments and healing. Established in 2008, it quickly became a national leader in narcolepsy research and awareness, as it is dedicated to funding research into the causes, prevention, treatments and a cure for narcolepsy while raising awareness among the public. Each year, Wake Up Narcolepsy hosts various awareness events and makes a substantial contribution to cutting edge research on narcolepsy. For more information, please visit:

About NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company led by an experienced management team with experience in the development and reorientation of product candidates to treat rare and complex disorders of the central nervous system. The Company’s flagship product candidate, Quilience®, is a proprietary sustained-release formulation of mazindol (mazindol ER) and is under development for the treatment of narcolepsy and potentially other sleep-wake disorders such as hypersomnia. idiopathic. Mazindol is a triple monoamine reuptake inhibitor and partial orexin-2 receptor agonist, which has been used for many years to treat patients with narcolepsy in compassionate use programs. A phase 2 study in the United States evaluating Quilience® in adult subjects with narcolepsy is currently underway. Previously, NLS successfully completed a Phase 2 study in the United States evaluating Nolazol ® (mazindol controlled release) in adult subjects with ADHD. The study met all primary and secondary endpoints and Nolazol ® was well tolerated. Quilience® has received orphan drug designation in the United States and Europe for the treatment of narcolepsy. Up to 1/3 of narcoleptic patients are also diagnosed with ADHD.

Safe Harbor Declaration

This press release contains forward-looking statements, expressed or implied, in accordance with United States federal securities laws. For example, NLS uses forward-looking statements when discussing mazindol as a potential treatment for narcolepsy and that it is potentially being developed for other sleep-wake disorders such as idiopathic hypersomnia. These forward-looking statements and their implications are based on the current expectations of NLS management only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. . The following factors, among others, could cause actual results to differ materially from those described in forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles in the initiation and / or success of its clinical trials; NLS products may not be approved by regulatory bodies, NLS technology may not be validated as it progresses, and its methods may not be accepted by the scientific community; NLS may not be able to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may arise with the NLS process; NLS products may end up being more expensive than expected; laboratory results may not translate to such good results in actual clinical settings; the results of preclinical studies may not correlate with the results of clinical trials in humans; NLS patents may not be enough; NLS products can harm recipients; changes in legislation may have a negative impact on the NLS; the inability to develop and introduce new technologies, products and applications in a timely manner; loss of market share and price pressure resulting from competition, which could cause the actual results or performance of NLS to differ materially from those contemplated in these forward-looking statements. Unless otherwise provided by law, NLS does not undertake to publish revisions of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unforeseen events. More detailed information on the risks and uncertainties affecting NLS is contained under “Risk Factors” in NLS’s Annual Report on Form 20-F filed with the SEC, which is available on the SEC website. ,

Corporate contact

Alex Zwyer, CEO: +41 41 618 80 00

Investor Relations Contact

Cindy Rizzo: +1 908-229-7050

Media contact

Pascal Nigen: +1 917-385-2160
Alpha Bronze, LLC

THE SOURCE: NLS Pharmaceutics Ltd.

See the source version on

Comments are closed.